UOC
IONS icon

UBS O'Connor’s Ionis Pharmaceuticals IONS Stock Holding History

UBS O'Connor’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,000
Closed -$98.1K – 553
2024
Q2 		$98.1K Sell
18,000
-2,000
-10% -$82K ﹤0.01% 432
2024
Q1 		$1.2K Buy
+20,000
New +$953K ﹤0.01% 509

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS O'Connor's IONS Position: Q3 2025 in Review

UBS O'Connor sold out of Ionis Pharmaceuticals (IONS) in Q3 2025, closing a stake of 81,251 shares — an estimated $3.21M sold.

UBS O'Connor first reported a position in IONS in Q4 2019 and held it in 15 quarters. The position peaked at $3.84M in Q1 2023. 436 funds tracked by Wall St. Rank hold IONS as of Q3 2025.

  • UBS O'Connor reported no remaining Ionis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 81,251 Ionis Pharmaceuticals shares in Q3 2025, an estimated $3.21M.
  • UBS O'Connor first reported a position in Ionis Pharmaceuticals in Q4 2019 and held it in 15 quarters.
  • UBS O'Connor's Ionis Pharmaceuticals position peaked at $3.84M in Q1 2023.
  • 436 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.